Table 1.
Characteristics of patients and controls.
| Patients with IBD | Control Group † | p1 | p2 | ||
|---|---|---|---|---|---|
| Crohn’s Disease | Ulcerative Colitis | ||||
| N (female) | 72 (33) | 66 (34) | 80 (40) | 0.505 | 0.837 |
| Age (mean ± sd) | 40.6 ± 14.5 | 44.6 ± 13.8 | 40.0 ± 10.0 | 0.096 | - |
| Age at IBD diagnosis #, n (%) | |||||
| A1 = Below 16 years | 13 (18.1) | 6 (9.1) | - | 0.162 | - |
| A2 = 17 to 40 years | 42 (58.3) | 42 (63.6) | |||
| A3 = Over 40 years | 9 (12.5) | 14 (21.2) | |||
| Disease localization #, n (%) | |||||
| L1 = Terminal ileum (CD) | 24 (33.3) | - | - | - | - |
| L2 = Colon (CD) | 8 (11.1) | ||||
| L3 = Ileocolon (CD) | 23 (31.9) | ||||
| L4 = Upper gastrointestinal tract (CD) | 8 (11.1) | ||||
| E1 = Proctitis (UC) | - | 4 (6.1) | - | - | - |
| E2 = Left-sided colitis (UC) | 38 (57.6) | ||||
| E3 = Pancolitis (UC) | 20 (30.3) | ||||
| Disease behavior # (CD), n (%) | |||||
| B1 = Nonstricturing, nonpenetrating | 31 (43.1) | - | - | - | - |
| B2 = Stricturing | 12 (16.7) | ||||
| B3 = Penetrating | 19 (26.4) | ||||
| B4 = Perianal | 1 (1.4) | ||||
| Current medication, n (%) | |||||
| No treatment | 6 (8.3) | 3 (4.5) | - | 0.476 | - |
| 5-ASA | 2 (2.8) | 16 (24.2) | <0.001 ** | ||
| Corticosteroids | 13 (18.1) | 25 (37.9) | 0.013 * | ||
| Immunomodulators | 28 (38.9) | 29 (43.9) | 0.605 | ||
| Biologicals | 19 (26.4) | 23 (34.8) | 0.355 | ||
* p < 0.05, ** p < 0.001 (for age, Student’s t-test; and for gender, age at diagnosis, and medication, chi-square test). CD, Crohn’s disease; UC, ulcerative colitis. † Control group consisting of healthy blood donors aged 20–60. # Age at IBD diagnosis, disease localization, and disease behavior (Crohn’s disease only) characterized according to Montreal Classification of IBD. p1: statistical significance between patients with Crohn’s disease and patients with ulcerative colitis; p2: statistical significance between patients with IBD in total and control group.